Becton, Dickinson and Company (NYSE:BDX) Q1 2026 Earnings Call Transcript February 9, 2026 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.91, expectations were $2.81.

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $2.91 in the first ...

Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 non-GAAP EPS and $5.25B revenue, surpassing ...

Becton, Dickinson and CompanyBDX, popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. Anticipated to ...

FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug ...

(RTTNews) - Becton, Dickinson and Co. (BDX) today announced that the U.S. FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, a next-generation device ...

State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a ...

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination ...

BDX Q1 FY2026 earnings call recap: strong results, Waters Life Sciences deal, $4B buybacks/debt paydown, and outlook amid tariffs.

BD (Becton, Dickinson and Company) has received 510(k) approval from the US Food and Drug Administration (FDA) for the EnCor EnCompass breast biopsy and tissue removal system. The approval marks the ...